Axis-Shield - A 'profitable' and relatively low risk growth play.

I have decided to take a cue from my earlier suggestion that Afinion US launch may provide an exit/reduction point. My recent re-entry was mainly a trading exercise (which also could have become the commencement of a new holding, news flow content pending etc), trading a stock is unusual for me. Obviously Afinion's launch is excellent news, however, the trading statements move to January unsettled me further, in other words it could be either, that the trading statement would counter the positive news flow of Afinion's US launch, or indeed the need to report on a full Homocysteine quarter? (or both), on that note I note CTT reported another quarterly decline in Homocysteine revenues -



Still interested, but again from the sidelines.